This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $8,016.30, is for the delivery of 840 mg/14 ml vials of the cancer medication Tecentriq (atezolizumab). It is a firm-fixed-price delivery order contract with a completion date of December 10, 2024. The award is not designated as a set-aside. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000, covering similar medical products and prescription drugs.
Generated 2/17/25, 9:41 PM